INSYS Therapeutics Inc clinical trials
The registry lists 45 studies whose lead sponsor is INSYS Therapeutics Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 1, 2019.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 45studies on the registry
- 0open to participants now
What it is testing
The drugs INSYS Therapeutics Inc’s studies test, most studies first; none is open now — 12 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- cintredekin besudotox1 in phase 30 open · 8
- 0 open · 6
- Fentanyl Sublingual Spray4 in phase 30 open · 6
- Cannabidiol3 in phase 30 open · 5
- 0 open · 3
- 0 open · 3
- 0 open · 3
- 0 open · 2
- 0 open · 2
- 0 open · 2
Show 2 moreShow fewer
- 0 open · 2
- Buprenorphine1 in phase 30 open · 1
All 45 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 08
- 09
- 10
- 11
- 12
- 13
- 14
- 515
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 15 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to INSYS Therapeutics Inc.
- INSYS Therapeutics Inc45 studiesSame company
Something wrong?
Focus areas
Conditions INSYS Therapeutics Inc leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 45 of 45.
- A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy VolunteersCompletedNCT03827629Phase 1
- A Study to Compare Bioavailability of Naloxone Nasal Spray, Naloxone Hydrochloride (HCl) Intravenous (IV) and Intramuscular Injection (IM) in Healthy VolunteersCompletedNCT03827642Phase 1
- Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative PainCompletedNCT03254459Phase 2
- Cannabidiol Oral Solution for Treatment of Refractory Infantile SpasmsTerminatedNCT02551731Phase 2
- Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure DisorderCompletedNCT02318602Phase 3
- Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate CancerWithdrawnNCT01188408Phase 2
- Fentanyl Sublingual Spray for the Treatment of Moderate to Severe Post-Operative PainCompletedNCT02915978Phase 2
- Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet SyndromeWithdrawnNCT02318563Phase 3
- Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut SyndromeWithdrawnNCT02318537Phase 3
- Fentanyl Sublingual Spray for the Treatment of Acute Procedure-related Pain in a Monitored SettingWithdrawnNCT02138409Phase 3
- Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe PainCompletedNCT02634788Phase 3
- Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe PainTerminatedNCT02310581Phase 3
- Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute PainWithdrawnNCT02137525Phase 2
- Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure DisordersCompletedNCT02324673Phase 1/2
- Fentanyl Sublingual Spray in Opioid Naive ParticipantsCompletedNCT02641340Phase 1
- Comparative Bioavailability of Dronabinol Oral Solution in Healthy VolunteersCompletedNCT02604992Not applicable
- Fentanyl Sublingual Spray and Fentanyl Citrate Intravenous (IV) in Opioid Naive SubjectsCompletedNCT02576353Phase 1
- Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy VolunteersCompletedNCT02477267Phase 1
- Possible New Therapy for Advanced CancerTerminatedNCT01832974Phase 1
- Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting ConditionsCompletedNCT02138396Not applicable
- Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 DaysWithdrawnNCT00024674Phase 1
- Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant GliomaCompletedNCT00024570Phase 1/2
- Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six DosesWithdrawnNCT00024687Phase 1
- Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant GliomaWithdrawnNCT00378235Phase 1/2
- A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid UsersCompletedNCT02094599Phase 1
- Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
- Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer PainCompletedNCT00538863Phase 3
- Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral MucositisCompletedNCT00956254Phase 3
- Pharmacokinetic Study of Fentanyl 400 µg Sublingual Spray, Actiq® 400 µg Transmucosally, and Fentanyl Citrate Injection 100 µg Intravenously (iv)CompletedNCT01780233Phase 1
- Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic CancerCompletedNCT01186731Phase 2
- Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast CancerCompletedNCT01190982Phase 2
- Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting ConditionsCompletedNCT01448772Phase 1
- IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant GliomaCompletedNCT00089427Phase 1
- Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced CancerCompletedNCT00046540Phase 1
- Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced CancerCompletedNCT00100672Phase 1
- Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced CancerCompletedNCT00100139Phase 1
- Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced CancerCompletedNCT00080418Phase 1
- Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid TumorsCompletedNCT01151384Phase 1
- Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma PatientsCompletedNCT00024557Phase 1
- Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced CancerCompletedNCT00024492Phase 1
- The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma MultiformeCompletedNCT00076986Phase 3
- Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant GliomaCompletedNCT00064779Phase 1
- Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant GliomaCompletedNCT00041587Phase 1/2
- Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced MalignanciesCompletedNCT00024648Phase 1
- Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid TumorsCompletedNCT00024661Phase 1